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Abstract. Mild cognitive impairment (MCI) is a syndrome defined as cognitive decline, but not sufficient to meet the criteria for
any specific dementia. Although subjects with MCI may have an increased risk to develop AD, this clinical state encompasses
several subtypes of cognitive dysfunction of different etiologies, none of which necessarily progresses to AD. The current inability
of clinical criteria to accurately identify this at-risk group for AD development is fuelling the interest in biomarkers able to
supplement clinical approaches. We recently described a blood-based cytofluorimetric method for conformationally altered p53
protein detection that allows the discrimination of AD patients from control subjects and patients affected by other dementias.
The same protein also predicted progression to AD in preclinical patients with MCI two years before clinical diagnosis of AD
was made. Herein, we describe these findings and discuss the potential of the test in diagnosing AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurode-
generative disorder characterized by irreversible cog-
nitive and physical deterioration. AD is the most com-
mon cause of dementia of the elderly population and its
incidence doubles every five years between 65 and 85
years of age. It also represents a growing public health
problem as life expectancy increases and the number
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of people with AD is expected to increase dramatically
from approximately 24 million people in 2001 up to
81 million worldwide by 2040 [1]. The treatment of
AD remains a major challenge because of an incom-
plete understanding of the events that lead to the selec-
tive neurodegeneration typical of AD brains. In view
of existing and emerging therapeutic compounds, the
focus has increasingly shifted to accurate detection of
the earliest phase of illness.
The degenerative process in AD probably starts 20–
30 years before the clinical onset of the disease [2]. This
clinical phase, between prodromal and established AD,
lies within the boundaries of the diagnosis of mild cog-
nitive impairment (MCI), during which subjects have
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measurable cognitive deficits,but not sufficient to fulfill
criteria for any specific dementia [3,4]. In particular,
MCI subjects show the presence of subjective memory
impairments, objective memory performance changes,
and declining financial skills [5], whereas other cogni-
tive functions and daily activities remain normal [6].
Although it is documented that subjects with MCI
have an increased risk of AD, this clinical state encom-
passes several subtypes of cognitive dysfunction of var-
ied etiologies, none of which necessarily progresses to
AD [7]. In particular, MCI subclassifications include
an amnestic form (aMCI), characterized by isolated
memory impairments, and one non-amnestic (naMCI)
in which other cognitive functions rather than memo-
ry are mostly impaired [8]; within these groups, aM-
CI subjects showed 8.6-fold higher odds of developing
AD [9]. Furthermore, it has been determined that pa-
tients suffering from aMCI progress to AD at a rate of
12 to 28% per year [3,10], whereas other MCI subjects
improve, reverting to a normal level of cognitive func-
tioning [11] and some die [12], thus underlining multi-
ple etiologies for MCI. Hence, within this context, there
is a need to reliably predict which patients with MCI
will progress to AD. The current inability of clinical
criteria to accurately identify this at-risk group is fu-
elling the emerging interest in biomarkers to potentially
supplement clinical approaches.
Within this reference frame, we studied p53 in aged
controls and demented patients finding that the con-
formational state of p53 protein in blood cells allows
the differentiation of AD patients from control subjects
and patients affected by other dementias. The notions
about p53 come mainly from oncology. p53 has been
described as a the guardian of the genome [13]. It is ac-
tivated in response to certain stressful situations, induc-
ing either cell cycle arrest and DNA repair or apopto-
sis [14]. The full-length p53 molecule comprises three
major domains; the N terminus transactivation domain,
the core DNA-binding domain, that is stabilized by a
Zn2+ atom coordinated by a histidine and four cys-
teines, and the C terminus tetramerization domain. p53
is mutated in about half of all human cancers, with 95%
of these mutations occurring in the core domain [15].
In particular, the core domain is endowed with high
flexibility, and certain missense mutations inside this
central domain can affect tertiary structure of the pro-
tein. Thermodynamic studies of p53 cancer mutations
have identified three major phenotypes classified as: i)
mutation affecting DNA contacts that have little impact
on protein folding; ii) mutation disordering local struc-
ture leaving more than 85% of the protein in folded
Table 1
Demographic and clinical variables and genotype frequency of the
APOE polymorphisms of all the subjects. N: number; M: male; F:
female; L.O.I.: length of illness; MMSE: Mini-Mental State Exam-
ination. Data are expressed as mean ± standard deviation. For the
genotype frequency values are expressed as number (%)
CTR AD MCI
N (M;F) 45 (20;25) 45 (9;36) 28 (5;23)
mean age ± SD 75 ± 12.6 81 ± 7.2 69 ± 12.4
L.O.I. (month) 52 ± 23 19 ± 6
MMSE 28.4 ± 1.6 14 ± 5.5 27.3 ± 2
Genotype CTR AD MCI
ε2/ε3 5 (11) 2 (4) 3 (10.7)
ε3/ε3 35 (78) 25 (56) 17 (60.7)
ε3/ε4 5 (11) 14 (31) 7 (25)
ε2/ε4 0 0 1 (3.6)
ε4/ε4 0 4 (9) 0
conformation; and iii) mutations globally denaturating
the core domain, thus resulting in more than 50% of
unfolded isoform [16–19]. This third phenotype is rec-
ognized by PAb240 antibody, since its epitope is cryp-
tic when p53 is in wild type conformation and becomes
accessible only when the core domain is denatured. It
should be stressed that conformational changes of p53
can also be due to posttranscriptional modifications in
the absence of specific mutations [20–23].
Within this context, the presence of an altered un-
folded p53 isoform was found enhanced in AD patients
in comparison with control and other types of demen-
tia [24]. Notably, the best sensitivity and specificity
of this marker was observed at ages  70 years [24],
suggesting the idea that unfolded p53 could also be
detected in the early stage of the disease.
On this basis, the purpose of our study was to further
investigate whether conformationally altered p53 ex-
pression may be applied to those patients falling in the
ill-defined category of MCI and in particular to predict
which subjects among MCI patients will progress to
AD.
MATERIALS AND METHODS
Subjects
Venous blood samples from healthy people and from
patients affected by MCI and AD were obtained from
Sant’Orsola Hospital in Brescia, Italy. This population
consisted in a group of 45 patients with sporadic AD, 45
healthy age-matched controls (CTR), and 28 patients
with MCI (Table 1).
The protocol of the study, including the follow-up
visits, was approved by the Ethical Committee and a
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written consent was obtained from all subjects or,where
appropriate, their caregivers.
All the subjects were examined by a senior neurolo-
gist or geriatrician and diagnosis of dementia was made
according to DSM-IV and the NINCDS-ADRDA cri-
teria. All MCI subjects met the original Petersen/Mayo
criteria for MCI [3,7]. Dementia was diagnosed based
upon interview, objective and neurological examina-
tion, cognitive evaluation, laboratory and radiological
(CT scan) investigation. Cognitive status was quantified
using the Mini Mental State Examination (MMSE). All
AD patients fulfilled the criteria for probable AD [25]
and were classified as “sporadic” on the basis that they
lacked a familial history of the disease, as acquired from
interviews with first degree relatives. Control subjects
were aged individuals with no clinical signs of neuro-
logical or psychiatric diseases, mostly enrolled among
spouses of the AD group of patients. None of the sub-
jects selected in this study was affected by neoplastic
or autoimmune disease when the blood samples were
taken. For each subject, the count of leukocytes was
within the regular interval clinical frame.
After two years from the recruitment, all 28 MCI
subjects were recalled and examined by the geriatri-
cian. The progression to AD was diagnosed based up-
on interview, objective and neurological examination,
cognitive evaluation, laboratory and radiological (CT
Scan) investigation.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were
isolated by centrifugation on a Ficoll Hipaque density
gradient from Na+/citrate samples (Eurobio, Italy) and
fixed in 2% formaldehyde in PBS. Rinsed cells were
permeabilized with 0.2% saponin in PBS solution and
incubated in ice for 30 min with a primary monoclon-
al antibody recognizing unfolded p53 (clone PAb240;
NeoMarkers, Fremont, CA) (4 µg/ml in PBS/1% BSA
solution). In particular the PAb240 antibody recognizes
the epitope 211–217 aa inside the core domain, which is
accessible only when the core domain is denatured and
the protein assumes an unfolded tertiary structure, thus
discriminating the so called “mutant-like” isoform [22].
Cells rinsed in PBS/1% BSA were incubated for 30
min in ice with a goat anti-mouse IgG antibody phyco-
erythrin (PE)-conjugated (DakoCytomation, Denmark;
1:40 in PBS/1% BSA). After rinsing, few microliters of
cell suspension were deposed on a glass slide and ob-
served with a fluorescence microscope Olympus BX51
with blue excitation (BP450–480 nm, DM 500, and
barrier filter 515 nm) equipped with a Camedia dig-
ital camera. Samples were observed at 40X magnifi-
cation. Pictures were taken with the same instrumen-
tal setting. Orange-red fluorescence from AD positive
cells was compared with the background fluorescence
of control samples as a technical control of the exper-
imental setting. The percentage of PAb240 positive
cells was quantified by cytofluorimetric analysis. Cell
suspension was analyzed with a flow cytometer Partec
PASII (Partec, Germany). PBMC population was iden-
tified by forward and side angle scatter (FSC, SSC) and
mutant p53 emission was detected in the FL-2 channel
(535–580 band pass filter). For each sample, data from
20000 events were recorded in list mode, displayed
on logarithmic scales and analyzed using WinMDI 2.8
software.
Molecular genetic analysis
Genomic DNA was extracted from peripheral leuko-
cytes by proteinase K digestion and standard phe-
nol/chlorophorm extraction procedure. The APOE gene
polymorphisms were determined by Hha I restriction
endonuclease digestion of PCR products, according to
Hixson and Vernier [26].
Statistical analysis
The data were analyzed by analysis of variance
(ANOVA) followed when significant by an appropriate
post hoc comparison test. Differences were considered
significant when a p-value 0.05 was attained.
RESULTS
118 subjects were enrolled among those referring
to the Department of Geriatric Medicine, S. Orso-
la Fatebenefratelli Hospital in Brescia, Italy. Control
subjects and AD and MCI patients were comparable
as far as age and gender distribution (see Table 1).
The distribution of ε2/ε3/ε4 alleles of APOE was
0.022/0.733/0.244 in AD cases, and 0.056/0.889/0.056
in control subjects; the frequency of the APOE ε4 allele
was, as expected, higher in AD population than in con-
trol subjects. MCI showed a distribution of ε2/ε3/ε4
alleles of APOE of 0.071/0.786/0.143.
Blood mononuclear cells derived from AD and MCI
patients and healthy subjects were subjected to cytoflu-
orimetric analysis using the conformational specific an-
tibody, PAb240, which discriminates unfolded p53 ter-
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Fig. 1. p53 protein expression in blood cells from AD, MCI, and non-AD patients. (A) Box plot reporting the amount of conformationally
altered p53 (%) expressed in peripheral blood cells for each subject enrolled in this study. Patients are divided according to the diagnostic group.
Tukey-Kramer Multiple Comparisons Test has been used for statistical analysis. **p < 0.01, ***p < 0.001 vs. control. (B) Quantitative analysis
of conformationally altered p53 expression after flow-cytometric analysis. Panels a, b, c, d, e, f are histograms reporting the fluorescence due to
conformationally altered p53 expression (FL-2) vs the number of reacting cells (events). For each histogram the correspondent statistical analysis
is reported.
tiary structure. We only analyzed this population, since
we previously demonstrated by immunofluorescence
staining the presence of false positive cells, identified as
granulocytes, showing under fluorescence microscope,
a light diffuse mostly non specific signal, compared to
the strong positivity to PAb240 antibody in monocytes
and lymphocytes [24]. A highly statistically significant
difference was found in the percentage of PAb240 pos-
itive cells when comparing controls with patients af-
fected by MCI or AD subjects (percent of PAb positive
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A) B)MCI with progression to 
Alzheimer’s disease
MCI without progression to 
Alzheimer’s disease
Fig. 2. Scheme of converted and not-converted MCI patients based on unfolded p53 analysis and APOEε4 genotype. Twenty-eight MCI (5 males
and 23 females) with a mean± standard deviation age of 69± 12.4 and MMSE score of 27.3± 2 were examined. Cognitive status was quantified
using the Mini Mental State Examination (MMSE). None of the subjects selected in this study was affected by neoplastic or autoimmune disease
when the blood samples were taken. Patients were divided in three groups according to APOEε4 variant and high unfolded p53. Two years later,
patients were re-evaluated and classified as converted and non-converted in AD (A, B).
cells, mean± SD; control subjects: 23.4± 11.9; MCI:
30.6± 10.7; AD: 35.1± 11.3; MCI versus controlP <
0.01, AD versus control P < 0.001) (Fig. 1).
To better characterize the nature of this different ex-
pression among AD, MCI, and control subjects, we
evaluated whether the expression of conformational
mutant p53 showed a correlation with some parameters
linked to AD. As previously reported [24], a statistical-
ly significant correlation was observed only when the
expression of mutant conformational p53 and the age of
both control subjects and AD patients were considered,
thus confirming in another independent population that
conformationally altered p53 is an age-dependent fac-
tor (data not shown).
Focusing on MCI group (28 patients), we found that
8 of them expressed APOEε4 allele. In addition, mea-
surement of the percentage of PBMC expressing un-
folded p53 of MCI patients defined two well separated
groups. The division in two groups was made consid-
ering one standard deviation over control mean (calcu-
lated reference value 35.3%), consistently with other
previous data from literature [27].
The first group (n = 20) had percentages of unfold-
ed p53 values ranging from 19.5% to 29.1% and the
other group (n = 8) expressed values ranging 38.2% to
60.3%. The latter was candidate at high risk to develop
AD, according to our previous indications [13]. Thus,
according to the predicted criteria, 16 patients (8 with
APOEε4 and 8 with high unfolded p53) were at high
risk to develop AD.
Interestingly, the follow-up of MCI patients at two
years from recruitment revealed that 14 out of 28
MCI patients converted to AD (Fig. 2). Among these,
six had high values of unfolded p53, three expressed
APOEε4 variant, and one had both high unfolded p53
and APOEε4. Four of the novel AD diagnoses were
not predicted either by the APOE genotype or by
p53 conformational state (Fig. 2A). Among the non-
converted group (14 patients), four expressed the ε4
variant of APOE gene and only one had high unfolded
p53 (Fig. 2B). Moreover, in the MCI converted group,
the expression of conformational altered p53 was inde-
pendent from distribution of ε4 allele of APOE (Fig. 2).
This is also consistent with our previous work [28],
demonstrating that the presence of the ε4 allele of
APOE does not influence the level of conformational
mutant p53 expression. The combination of APOEε4
allele and unfolded p53 yielded a sensitivity of 71.4%
and a specificity of 84%, comparable with data reported
by Zetterberg et al. [29] on cerebrospinal fluid (CSF)
biomarkers.
DISCUSSION
Recent research suggested that onset of AD is com-
monly preceded by an interim phase known as MCI.
Since MCI diagnosis may include patients in a transi-
tional state between prodromal and full blown AD, it
is considered a window of therapeutic opportunity for
treating patients prior to symptom onset [3], even if the
102 C. Lanni et al. / Unfolded Blood p53 as Predictive Signature from Mild Cognitive Impairment to AD
presently available treatments are mostly symptomatic.
On the other hand, important new pharmacotherapeu-
tic options will likely become available only over the
next decade, considering the variety of drug targets and
mechanisms of action identified and the total number
of compounds under investigation [30]. In view of ex-
isting and emerging therapeutic compounds, there is
increasing interest to develop techniques allowing an
accurate detection of the earliest phase of the disease.
The introduction of biological markers in the clinical
management of AD will not only improve diagnosis
relating to early detection of neuropathology with un-
derlying molecular mechanisms but also provide tools
for the assessment of objective treatment benefits.
Measurement of p53 conformational status in blood
cells has been found to discriminate AD cases from
normal aging, Parkinson’s disease, and other demen-
tias [24]. In particular, the measurement of conforma-
tionally altered p53 has been demonstrated to be highly
sensitive mainly in young patients with a sensitivity of
90% in subjects below 70 years of age [24]. Since p53
conformational changes found in AD cells have been
demonstrated to be independent of gene mutations [31],
it is reasonable to wonder about the mechanism by
which p53 changes its conformational state. This issue
is actually under investigation in our laboratory. On
the other hand, a pathogenic link between p53 confor-
mational changes and AD was indirectly suggested by
the effects of low soluble concentrations of amyloid-β
(Aβ) on p53 tertiary structure in fibroblasts [32] and
other cell lines [33]. It is noteworthy that Aβ and pro-
oxidant conditions may induce conformational changes
in p53. The effect itself of Aβ on p53 misfolding can
be counteracted by vitamin E [33]. Indeed, pro-oxidant
conditions in MCI and AD patients [34] may have driv-
en the observed changes in PBMC. In addition the pos-
sibility that the p53 misfolding in MCI and AD patients
reflects an overall propensity to protein misfolding can-
not be ruled out.
In this study, to assess whether p53 conformational
changes are an early event in AD pathology, we fol-
lowed up patients falling in the MCI category for two
years. Analysis of unfolded p53 was performed at the
beginning of the enrollment and was used to predict
which subjects among MCI patients will progress to
AD. The results obtained in the present study confirm
and extend the previous observations on AD patients.
Furthermore, we found that a cytofluorimetric approach
for conformationally altered p53 protein was able to
predict progression to AD in a small cohort of preclin-
ical patients with MCI two years before clinical diag-
nosis for AD was made. The rate of progression of
MCI to AD was comparable with the mean reported in
population studies [3,10]. In fact we found that 50%
of MCI patients converted to AD after two years from
the recruitment. The high expression of unfolded p53
may be considered as high risk factor for the conver-
sion to AD (among 8 patients with elevated unfolded
p53 seven converted). In fact, in the MCI converted
group, 50% was predicted based on elevated levels of
conformationally altered p53, whereas only 28% was
predicted based on APOE status. Noteworthy, higher
levels of mutant conformational p53 and APOEε4 ap-
peared to be independent risk factors for AD even if
numbers are small to be strong at this point. In line with
our previous data [28], complexively the mutant con-
formational p53 may be considered as a marker useful
in the ε4 negative younger patients ( 70 years).
Interestingly enough, when we combined the data on
p53 and APOEε4, we obtained a calculated sensitivity
of 71.4% and a specificity of 84% for the predictive
test. Intriguingly, this accuracy was comparable with
data reported by Zetterberg et al. [29] on combined CSF
biomarkers.
The fact that p53 was able to identify only a subset
of converting patients is consistent with the idea that
single biomarkers may not have sufficient sensitivity to
detect all cases of the disease or adequate specificity
to distinguish one pathology fingerprint from other dis-
ease profiles. For this reason is important to identify a
battery of determinations to increase the accuracy of the
diagnosis. In this context, several studies have showed
that selected combinations of preclinical markers may
predict this conversion [35–37]. The combined use of
cognitive tests, APOE genotype and a neuroradiologi-
cal technique has been proposed as the best option for
prediction, showing an accuracy > 90% [38]. Other
research groups focused on CSF, total-tau/Aβ1−42, and
magnetic resonance imaging (MRI) biomarkers, such
as hippocampal, entorhinal, and ventricular volumes
and brain atrophy rates, finding that their combination
provides better prediction than either source of data
alone [39,40], with a diagnostic accuracy of 80–90%.
However, it is difficult to prepare a patient for all these
analyses and sequential studies appear difficult to per-
form, making routine testing not practical in elderly
at-risk patients. This emphasizes the need for simple
not invasive tests, useful to provide biomarkers that
can identify MCI patients declining to AD. Search of
biomarkers in the blood compartment has seen the sig-
nificant contribution of the groups directed by Wyss-
Coray. They developed a proteomic analysis of 18 pro-
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teins in the plasma of patients able to predict with 90%
accuracy the diagnosis of AD [41]; furthermore these
18 proteins showed a potential in identifying patients
with MCI who progress to AD [42]. However, the
proteomic approach lacks of the identification of post-
transcriptional protein modifications deriving from bio-
chemical and metabolic events linked to the develop-
ment of the pathology.
Here we found that high values of unfolded blood
p53, which has been linked to AD pathology, may be
considered as high risk factor for the conversion to
AD and, when associated with APOEε4 genotype, it
yielded sensitivity and specificity values comparable to
those obtained by a combination of CSF biomarkers.
We are aware that the sample size of our study is too
small to reach a definitive conclusion and the definition
of conformationally altered p53 as predictive signature
for MCI to AD requires a further investigation in larger
and independent populations of patients, which is at
the moment under investigation. Anyway, we suggest
that measurement of conformational p53 state can be
useful as an easy accessible adjunctive diagnostic tool
in identifying those in the at-risk group of MCI patients
who progress to AD.
Finally, it is important to underline that we cannot
speculate at this time whether conformational altered
p53 found in AD peripheral cells is also present in the
brain of AD patients and the relevance of such impair-
ment in terms of neuronal function. Studies in this di-
rection are now in progress in our laboratory. There
are, however, previous postmortem studies suggesting
an involvement of p53 in degenerating neurons in AD.
These include de la Monte and colleagues [43] showing
increased p53 and Fas expression in specific popula-
tions of cortical neurons; Kitamura et al. [44] showing
increased amount of p53 in temporal cortex, mainly lo-
calized in glial cells; and Seidl et al. [45] showing high-
er levels of p53 in frontal and temporal lobe from Down
syndrome patients. On the other hand it is not known
whether the increase in p53 observed in the quoted pa-
pers occurs in degenerating neurons and/or reflects the
expression of a conformational altered isoform of p53,
as we detected in blood cells and fibroblasts from AD
patients [24,31,32].
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